Global Enzymatic Debridement Market By Type (Collagenase Product, and Papain Product), By Application (Hospitals, and Clinics), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Enzymatic Debridement Market By Type (Collagenase Product, and Papain Product), By Application (Hospitals, and Clinics), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Global Enzymatic Debridement Market by product type (Collagenase, Papain, Other), By end user (Hospitals, Clinics, others) and by Region -Global Forecast to 2028.,Which offers a holistic view of the global Enzymatic Debridement market through systematic segmentation that covers every aspect of the target market.

The global Enzymatic Debridement market is projected to be US$357.7 Mn in 2020 to reach US$ 809.5 Mn by 2030 at a CAGR of 8.5%.

The process by which the dead tissue from a wound is removed is called Debridement. When the chemical enzymes are used to treat dead tissue, it is referred to as enzymatic Debridement. The chemicals used for enzymatic debridements like bromelain, streptokinase, papain, validate and collagenase are obtained from plants and Micro-organism. This method is more set at aiming towards dead tissue compared to when body cells do the same, according to Wound Care Practices. The replacement of dead tissue is required for wound healing and healthy tissue formation. If this process of removal of tissue is not done in time, this might lead to infections and subsequent problems. Enzymatic debridement is much speedier than autolytic debridement. The process is simple to perform, and its very functional. Enzymatic debridement restricts bacterial overgrowth and other diseases that might cause sepsis, pain and further amputation.


Global Enzymatic Debridement Market Revenue (US$ Mn), 2021 to 2030


Increasing awareness among patients about enzymatic debridement in the treatment of wound care and technological advancement and government initiatives for strengthening the overall healthcare infrastructure is expected to boost the enzymatic debridement market.

Different factors like increasing burn injuries, diabetic foot ulcers and growing geriatric population are expected to fuel the growth of the target market.
However, high prices of advanced wound care products are expected to hinder the growth of the target market.

Global Enzymatic Debridement market is segmented on the basis of product type, end-user and region. On the basis of product type, the market is segmented into collagenase product, papain product and other product types. The collagenase product accounts for the majority share in the global Enzymatic Debridement market, while the papain product is expected to register significant growth rate over the forecast period. On the basis of end users, the market is segmented into hospitals, clinics and other users. The hospitals account for a majority share in the global Enzymatic Debridement market, while the share of clinics follows it.


Global Enzymatic Debridement Market by End-user, 2018


On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East Africa. North America accounts for the majority share in the global Enzymatic Debridement market due to technological advancement and government initiatives for strengthening the overall healthcare infrastructure, followed by Europe. Emerging economies such as Asia-Pacific; China and India are expected to register the highest growth rate over the forecast period. South America and the Middle East and Africa are expected to register stable growth over the forecast period. North America region is the largest supplier of enzymatic debridement; Europe is the second largest supplier of enzymatic debridement. North America and Europe are the largest consumption places.

The research report on the global enzymatic debridement market includes profiles of some of the major companies such as Smith and Nephew Plc., Virchow Biotech Private limited, MediWound Ltd., WeiBang Biopharm and Stratus Pharmaceuticals Inc.



Below are the active patents related to Enzymatic Debridement Market.


Patent Number: US20130156745A1

Composition for enzymatic debridement

Abstract

Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.

Application File Date: 2012-12-18

Application Granted Date: 2018-08-28

Current Assignee: KCI Licensing Inc

Patent Number: US20050202071A1

Apparatus and methods for enzymatic escharotomy in burn induced compartment syndrome

Abstract

Apparatus suitable for use in the prevention and treatment of burn induced compartment syndrome facilitates the rapid and efficient deployment of enzymatic compositions to the affected limb or limbs of a burn victim suffering from a circumferential burn. The apparatus includes a flexible, water-impermeable generally cylindrical covering layer. The covering layer has an inner surface facing the limb and an outer surface. The covering layer has a proximal sealable open end through which the burned limb is inserted and a distal closed end. An enzymatic escharotomy agent is contained within the covering layer. The covering layer retains the enzymatic escharotomy agent in close proximity to the burned limb, and the apparatus is enclosed within a sterile sealed package evacuated from moisture. In use, the burned limb is enclosed within the apparatus, and the enzymatic escharotomy agent is activated in situ by contacting the agent with hydrating fluid, thereby inducing enzymatic escharotomy of the circumferential burn.

Application File Date: 2004-10-21

Application Granted Date: 2010-09-14

Current Assignee: MediWound Ltd

Key Market Segments

By Product Type

  
Collagenase Product
  
Papain Product
  
Others

By Application

  
Hospitals
  
Clinics
  
Others


Key Market Players included in the report:


  
Advanced Medical Solutions Group
  
ArthroCare Corporation
  
Coloplast A/S
  
Derma Sciences
  
MediWound Ltd.
  
Misonixnc
  
Smith & Nephew plc
  
Stratus Pharmaceuticals Inc.
  
PuriCore
  
Virchow Biotech Private Limited
  
WeiBang Biopharm


Below are the key development related to Enzymatic Debridement Market in 2020 and 2021.


April 2021: MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx. MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced it has enrolled the first patient in its phase 2 pharmacology study of EscharEx®, its next-generation enzymatic debridement agent under development for chronic wounds, with data expected in the second half of 2021. Source

Mar 2021: American Medical Technologies and RestorixHealth Announce Transformational Merger to Create Industry-Leading Advanced Wound Care Management Company
Transformative Combination to Take Advantage of Complementary Cross-Selling Opportunities Across Multiple Care Settings and Wound Care Service Offerings. American Medical Technologies ("AMT"), an independent provider of wound care, ostomy, urology and tracheostomy supplies and services to long term and post-acute care facilities, and RestorixHealth ("Restorix"), a leading wound care management company that offers comprehensive wound care services across 236 outpatient wound care clinics and multiple at-home service offerings, announced a transformational merger to create the leading wound care services platform to better serve the patients, referral sources and managed care partners of both companies. Financial terms of the transaction were not disclosed. Restorixs rapidly growing offerings in wound care supplies and at-home physician services will be strengthened by AMTs existing platform, commercial contract footprint and supplies expertise. In addition, AMT will leverage Restorixs at-home platforms to accelerate growth. Source

January 2021: Locate Bio’s CognitOss Granted FDA Breakthrough Device Designation.CognitOss is designed to treat osteomyelitis, a debilitating inflammatory bone infection.FDA’s Breakthrough Device Program helps accelerate patient access to more effective treatments. Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to CognitOss, currently in development for the treatment of chronic osteomyelitis. The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Osteomyelitis is a progressive, inflammatory infection of the bone, usually caused by bacteria and is estimated to account for up to 50% of all non-trauma related amputations. Currently, the standard treatment for chronic osteomyelitis is surgical debridement, long-term, high-dose administration of antibiotics, and – for larger defects – bone grafting which often requires a second surgical procedure to remove the non-resorbable bone graft. CognitOss is intended to offer surgeons a single surgical procedure alternative, combining a fully resorbable bone graft with best-in-class bone healing properties and a proprietary dual-phasic release of antibiotics, to initially provide a bolus release at the site of the infection and then prevent re-infection through a further controlled release. CognitOss is intended to be used as an adjuvant to oral or intravenous antibiotics, to prevent colonization of the graft material. Source

July 2020: Bioventus Makes $15 Million Equity Invesment in CartiHeal with an Agreed Option Structure to Acquire Company Upon Milestone Achievements. KFAR SABA, CartiHeal, developer of the proprietary Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured an additional $15 million equity investment from Bioventus, a global leader in orthobiologics. The investment follows the recently completed enrollment and outcome of interim analysis in CartilHeal’s investigational device exemption (IDE) multinational pivotal study. An additional $5 million can be secured by CartiHeal from Bioventus, if needed, for IDE study completion. Source

July 2020: The successful enrollment and outcome at the interim analysis of CartiHeal’s pivotal study for Agili-C implant is an important milestone. New round of funding is expected to enable CartiHeal to complete all patient follow-up in the study and submit a first application for premarket approval (PMA) to the FDA. Bioventus made an initial $2.5 million investment in the Agili-C IDE study in January 2018, as part of a previous financing round. Bioventus and CartiHeal have agreed on an option structure under which Bioventus will acquire the company shortly after FDA approval of the Agili-C implant. Terms of that option structure are not disclosed. Source